Application of One-Step Nucleic Acid Amplification (OSNA) in different cancer entities and usefulness in prostate cancer: a systematic review

Abstract

Background Lymph node (LN) status is a key prognostic factor in the decision-making process of different cancer entities, including prostate cancer (PCa). Sectioning and haematoxylin and eosin (H&E) staining technique remain the gold standard for the evaluation of LN metastases despite some limitations, especially low sensitivity in detecting an accurate tumour burden within the LN, as well as a subjective and time-consuming result. One-step nucleic acid amplification (OSNA) quantifies mRNA copies of cytokeratin 19 (CK19) in a fast, objective, automated, and reproducible way, raising a general interest to explore its utility for lymphatic metastasis identification in different malignancies. Methods To present the latest evidence related to the detection of LN metastases in several tumours by using OSNA compared with the conventional H&E method, a systematic review of articles published since March 2021 was conducted using PubMed, Cochrane Library, and Web of Science databases. References from primary papers and review articles were checked to obtain further potential studies. Our procedure for evaluating records identified during the literature search followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses criteria. With the aim to design and justify future clinical routine use of OSNA in PCa, novel PCa evidence has been included in this review for the first time. Results Twenty five studies were included. LN from six different groups of tumours: breast, gastrointestinal, gynecological, lung, head and neck and prostate cancers has been assessed. OSNA was compared with post-operative formalin-fixed paraffin-embedded tissue sections with H&E staining as the reference standard. Contingency tables were created, and concordance rate, sensitivity, specificity and predictive values were reported. Seventeen studies analysed the discordant cases using different techniques. Conclusion OSNA method has a high diagnostic accuracy for the detection of LN metastases in several CK19 expressing tumours. Available evidence might encourage future investigations about its usage in PCa patients to improve LN staging and prognosis.

Diagnostic of Cytokeratin-19 Gene Expression in Iranian Breast Cancer Patients

“…CK19 mRNA expression in peripheral blood has been associated with poor patient outcomes (29,30), and CK19 has been detected in the bone marrow and tumor cells from breast cancer patients via immunoassay (31) OSNA-CK19 has proven useful to detect sentinel lymph node involvement in breast cancer patients (32)(33)(34). CK19 is a marker expressed by several solid tumors of epithelial origin, but not by healthy lymphatic tissue, moreover, cytokeratin 19 (CK19) is a fast, objective, automated, and reproducible way, raising a general interest, to explore its utility for lymphatic metastasis identification in different malignancies (35). Our study developed a nomogram to predict non-sentinel lymph node metastasis for breast cancer patients with a positive axillary sentinel lymph node.…”